Maropitant Citrate Market

Key data points: Market size in 2027 = $147.1 million and 2035 = $247.6 million, growth forecast = 6.7% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in maropitant citrate market to 2035 by form (flavored tablet and injectable solution), species (cat and dog), distribution channel (offline pharmacy and online pharmacy), end use (animal specialty hospital, veterinary clinic, and veterinary hospital), and region (North America, Europe, Asia Pacific, and the Rest of the World) Maropitant Citrate Market The future of the global maropitant citrate market looks promising with opportunities in the animal specialty hospital, veterinary clinic, and veterinary hospital markets. The global maropitant citrate market is expected to reach an estimated $247.6 million by 2035 from $147.1 million in 2027 with a CAGR of 6.7% from 2027 to 2035. The major drivers for this market are the increasing prevalence of pet nausea disorders, the rising demand for animal health treatments, and the growing awareness of veterinary medications. • Lucintel forecasts that, within the form category, flavored tablet is expected to witness higher growth over the forecast period due to compared to traditional tablets, flavored tablets have better palatability and compliance. • Within the end use category, animal specialty hospital is expected to witness the highest growth over the forecast period due to growing rates of pet ownership has increased the need for specialty veterinary care. • In terms of regions, North America is expected to witness the highest growth over the forecast period due to ownership of companion animals and the availability of advanced veterinary care services. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Maropitant Citrate Market Between the years 2025 and 2027, it is expected that the market will develop with reliance on clinical data for the validation of therapeutic claims. It is expected that the market will thrive with the continuous demand for control of nausea in pets. The way clinic protocols and the use of the internet alter the way veterinarians practice, affects the way maropitant citrate is purchased and used. The maropitant citrate market is expected to flourish with the growing concern for the health and well-being of companion animals and the increasing acceptance of the use of antiemetic therapy. • Preventive Companion Animal Care: In 2025 and 2026, with the increasing demand for companion animal care and the continuous education of veterinary practitioners regarding the use of maropitant citrate for control of postoperative nausea and other chronic conditions, it is expected that use of maropitant citrate will further increase. • Generic and Multisource Supply: In the same years, increasing concerns for animal health and the growing acceptance of therapy with maropitant citrate have fostered the entry of multiple drug suppliers into the market, leading to a reduction in prices charged for the drug. • Maropitant Citrate: The ability to make different dosage forms, especially tablets and injections, beyond the current 1 mg/kg limit, is increasing; the products in development are expected to improve ease of administration and extend the use of the drug to field and shelter environments, 2025-2027. • Digital Veta Pharmacy: The use of online pharmacies by veterinary practices to fill prescriptions and offer home delivery and reminder services, increased in 2025. The trend is expected to improve the availability of maropitant citrate and other veterinary drugs, especially in remote areas, and enhance compliance in the medium term. • Quality and Manufacturing: The focus of regulatory agencies on pharmacovigilance is increasing, especially on the control of impurities and traceability, and this positively impacts the companies able to sustain high levels of control in their processes. Supply of quality maropitant citrate will be determined by the ability of manufacturers to meet the requirements of various veterinary regulatory agencies, 2025-2027. The increased demand for maropitant citrate will be matched by an improvement in the supply of the drug, predominantly in formulations that meet specific needs and require less compromise, 2022-2027. Transparency in the supply and demand side of the market will ease price negotiation. The presence of multiple manufacturers will encourage competition to improve product quality. Recent Developments in the Maropitant Citrate Market Maropitant citrate will see increased market activity from 2025-2027 as veterinary clinics want to have reliable antiemetics. Although Zoetis is the only company with Cerenia, maropitant citrate, other veterinary drug companies have been developing maropitant citrate as well. Lucintel expects that maropitant citrate will have a positive outlook due to increased spending by pet owners and the number of procedures performed on pets. • Generic Market Entry: Maropitant citrate tablets and injections were filed and/or approved in 2025 (March 2025). Barring other restrictions, maropitant citrate tablets and injections will be economically and functionally substitutable with Cerenia. Independently owned veterinary clinics will likely switch to the less expensive maropitant citrate tablets and injections. • Portfolio Extension: Zoetis gained FDA approval for Cerenia to be administered at a dose of 2 mg/kg for vomiting that occurs post-procedure (June 2025). Expanding Cerenia’s uses should assist in maintaining and/or expanding the company’s share of the market for antiemetics. • Contract Manufacturing: Several contract manufacturing companies focused on the production of veterinary injectable products expanded their capacity in 2025 (September 2025). Veterinary clinics will likely use alternatives to Cerenia if injectable shortages continue. • Digital Integration of Veterinary Medicine: In January 2026, several veterinary service and practice management companies incorporated digital workflows for the use of maropitant for the prevention of vomiting associated with chemotherapy and for postoperative nausea and vomiting. It is expected that with the introduction of these digital aids, the prescribing of maropitant for the management of these conditions will increase. These aids may also help collect real-world data on the use of maropitant for these conditions. • Pharmaceutical Regulation: In 2026 (April), several national regulatory agencies announced improvements to their inspections of veterinary medicine to include adverse event reports, reviews of product labels, and residue limits. It is anticipated that increased regulatory activities will result in an increase in costs to manufacture veterinary medicinal products and will result in the elimination of less establishment-banned (Quality) veterinary medicinal products from the market. It is anticipated that by 2027, the veterinary medicinal products market will remain the same, and brands will continue to compete on the effectiveness of their products and the reliability of their formulations. The greatest potential to win and retain market position is for companies that are first to provide reliable and effective veterinary medicinal products and adhere to the requirements of veterinary medicine regulations. Strategic Growth Opportunities in the Maropitant Citrate Market Growing rates of pet ownership and preventive veterinary care create a larger potential market for maropitant citrate for veterinary use from 2024 to 2026. Maropitant citrate is a highly effective anti-emetic and anti-vomiting medication. Accommodating market trends and ease of regulatory approvals should allow maropitant citrate to be prescribed for uses outside of traditional veterinary practice. • Anti-emetic Protocols for Cats and Other Exotic Pets: Veterinary clinics are conducting an increasing number of feline and exotic pet surgeries and need anti-emetic medications to control vomiting and nausea. The FDA approved Cerenia (a canine anti-nausea and anti-vomiting medication) in January 2005, and Cats are expected to benefit from this medication. Other species may also benefit from maropitant citrate and other anti-nausea and anti-vomiting medications in the next 3-5 years. • Premium Veterinary Care: Owners are willing to pay for anti-nausea and anti-vomiting medications to be administered prior to surgery and other expected situations. Zoetis, a veterinary pharmaceutical company, reported 2024 revenues of $9.5 billion. Anti-nausea and anti-vomiting medications are expected to be of greater value in the future due to bundling with other veterinary care services. • Urgent-care Veterinary Services: We anticipate continued, strong growth in emerging markets, including Latin America, the Middle East and India. India’s pet care market is projected to be $1.2 billion in 2025. Maropitant Citrate is approved for use in multiple countries and registration in India is expected to result in rapid market expansion. A veterinary distributor has recently launched Maropitant Citrate in India and it is expected that with additional partner veterinarians and smaller pack sizes, access and use will increase in the next 3-5 years. • Use in Hospital and Specialty Care: The use of maropitant citrate in the control of acute or post-operative nausea and vomiting in pets is well described. Oncology and emergency services are growing areas in veterinary medicine. The American Veterinary Medical Association reported in February 2025 there were over 125,000 veterinarians in the United States. Continued standardization of best practices in the use of maropitant citrate will facilitate its use in the control of acute and post-operative nausea and vomiting in pets in the hospital. • Use in Digital Veterinary Medicine: The increasing use of technology in veterinary practice to improve practice efficiency and maximize revenue can include the use of maropitant citrate for control of post-surgical nausea and vomiting. The digital or electronics integration in veterinary practice will improve practice efficiency and provide quantifiable outcomes in the next 3-5 years. The digital veterinary practice will facilitate the use of maropitant citrate for the control of nausea and vomiting in pets. The use of maropitant citrate will continue to increase in veterinary specialty and emergency care. In addition, the prevention of nausea and vomiting in other clinical situations (e.g. oncology, surgery and other clinical indications) will expand. Marketing opportunities will exist with suppliers and specialty veterinary clinics that focus on preventative medicine and empower clients with education and best practice guidelines. Maropitant Citrate Market Drivers and Challenges Various factors, including the animal health market in veterinary medicine, drug manufacturer’s interest, price, legal environment, and the supply chain, impact the market for maropitant citrate. Some factors restrict the maropitant citrate market, and others provide growth opportunities. According to Lucintel, these factors will have the largest effect on this market in the next 5-10 years. The factors responsible for driving this market include: • Rise in Demand for Companion Animal Health: Growing pet ownership and longer pet life led to an increase in the demand for veterinary health services. Maropitant citrate is a citrate salt of an appetitive anti-emetic. It is mainly used to control vomiting in various health conditions in dogs and cats. As per the latest edition of the veterinary text published in January 2025, the dose of maropitant citrate to be used to control acute vomiting is 2 mg/kg body weight. In the next three to five years, it is expected that, due to various social and economic changes and the later intervention of veterinarians, particularly in urban areas of developed countries, the demand for maropitant citrate will increase. It is expected that maropitant citrate will be prescribed to control various conditions in dogs and cats that cause vomiting. • Product Improvement and Range Extension: Product advances facilitate the development of better tablets and injectable products. Improvements in palatability, packaging, and other administration aids help increase compliance. The injection route of administration is often preferred when the animal does not retain the medication. Oral formulations are ideal when the medication needs to be administered in the animal’s home. Various administration routes of veterinary drugs can be employed in the same clinical case. The use of different formulations of a drug can increase the flexibility of a veterinarian in the treatment of a patient. It is likely that the use of novel formulations of veterinary drugs in the marketplace will increase during the next five years. These new formulations of veterinary drugs will assist veterinary drug distributors. • Growth of Veterinary Services: Investments in the veterinary sector by developing new clinics, hospitals, and diagnostic laboratories, has increased the availability of prescription veterinary drugs. Modern clinics and specialization enable veterinarians to identify and treat disorders such as post-operative nausea and vomiting. New veterinary protocols published in 2025, designated maropitant citrate to prevent vomiting, whether it be in the context of motion sickness or other forms of vomiting. It is likely that the use of telemedicine in combination with improvement of veterinary clinics, will increase the availability of veterinary drugs in the next five years, particularly in developing countries. • Regulatory Framework for Animal Medicines: Veterinary medicines must be approved by regulators, and manufacturers must comply with standards to establish and maintain pharmacovigilance systems. Prescribing veterinary medicines requires a valid prescription. Regulatory frameworks enable the veterinary profession to play an active role in shaping policies that govern the manufacture and import of veterinary medicines. There are approved veterinary references, and in February 2025, some references specified dosage for dogs and cats based on age and weight. It is expected that the harmonization of veterinary medicine regulations will result in the legal sale of maropitant citrate for dogs and cats during the next three to five years, and a decrease in the illegal sale of the product. • Manufacturing and Cost: Maropitant citrate is a relatively new product, and although there are several manufacturers, the costs of good manufacturing practices and other associated costs mean that a few manufacturers dominate the market. Improvements in technology and practices in the pharmaceutical field means that maropitant citrate may become more affordable for pet owners, and alternatives may be manufactured for veterinary use. In September 2025, some veterinary dosing references indicated that maropitant citrate may be used at a dose of 2 mg/kg for dogs and cats. The challenges facing this market include: • Safety, Approval, and Compliance Requirements: Many restrictions are placed on Maropitant citrate products including requirements for adequate product effectiveness, product labelling, product stability, and post-marketing reporting of product side-effects. Strict regulations can increase the cost and extend the time period for approval of veterinary pharmaceuticals, particularly for small pharmaceutical manufacturers. The veterinary labelling, which was updated in April 2025, included warnings for the targeted species, age limitations, and the potential side-effects of the product. In the next three to five years, the market can expect more stringent requirements, which can increase the cost of doing business. However, from the perspective of the overall health and welfare of animals, and supporting the confidence of the veterinarians, these requirements are appropriate. • Price Competition and Generic Substitution: Many competing products, including alternative antiemetics, and products manufactured in other countries can significantly diminish the market prices. Owner out-of-pocket expense, combined with insurance coverage, product availability, and other therapies, can impact the veterinary prescription. In July 2025, the most acceptable treatment regimens for various indications required Maropitant citrate to be administered in conjunction with other products. Product dosage is weight-based; therefore, price and product consumption vary based on animal size. During the next three to five years, other pharmaceutical companies will introduce similar products, further increasing price competition. • Supply-Chain Risks and Demand Changes: There are several reasons to expect disruptions in the supply of veterinary medicines. These reasons include the use of specialized active pharmaceutical ingredients, reliance on international suppliers and distribution sites, temperature-controlled distribution, and gaps in supply and distribution. Demand may also change, for example, because of seasonal variations in travel, the level of activity in the surgical schedule, and the occurrence of illnesses. In 2025, veterinary practices relied on the supply of various medicinal products to provide different services. Stabilizing the supply of these products posed a challenge. It is expected that in the following years, there would be changes in the supply of the products. Therefore, product suppliers may need to depend on different sources of supply, produce the products in different regions, and hold safe and adequate supply of the products. The veterinary antiemetic market is expected to grow because of the increasing interest of pet owners in pet health and wellness, as well as the growing pet health infrastructure. Improvements in antiemetic products and the awareness of the veterinary profession may also create a positive outlook on the market. It is expected that a product would be first produced by a company and, because of the awareness of the product, the competition would increase. Price cutting and the introduction of lesser-quality products by new market participants may result in margin compressions. Thus, in the next few years, it is likely that participants in the market would rely on their veterinary distribution channels to improve the supply of antiemetic products. The outcome would depend on the extent to which companies in the market would be able to innovate antiemetic products and serve the market needs, while ensuring adherence to regulations. List of Maropitant Citrate Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies maropitant citrate market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the maropitant citrate market companies profiled in this report include- • Zoetis Inc. • Teva Pharmaceutical Industries Ltd. • Sandoz International GmbH • Apotex Inc. • Hikma Pharmaceuticals PLC • Zydus Lifesciences Limited • Dechra Pharmaceuticals plc • Vetoquinol S.A. • Ceva Santé Animale S.A. • Virbac S.A. Maropitant Citrate Market by Segment The study includes a forecast for the global maropitant citrate market by form, species, distribution channel, end use, and region. Maropitant Citrate Market by Form [Value ($M) from 2019 to 2035]: • Flavored Tablet • Injectable Solution Maropitant Citrate Market by Species [Value ($M) from 2019 to 2035]: • Cat • Dog Maropitant Citrate Market by Distribution Channel [Value ($M) from 2019 to 2035]: • Offline Pharmacy • Online Pharmacy Maropitant Citrate Market by End Use [Value ($M) from 2019 to 2035]: • Animal Specialty Hospital • Veterinary Clinic • Veterinary Hospital Maropitant Citrate Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Maropitant Citrate Market Regulations on veterinary drugs, the expansion of companion animal services, and the investment in controlled drug manufacturing have been key growth drivers for the maropitant citrate market. From 2025 to 2027, maropitant citrate manufacturers and distributors have focused on portfolio compliance and the adaptation of supply chain flexibilities. In 2022, based on our analysis, differences in maropitant citrate product approvals at the country level still meant something at the market level. • United States: The FDA's focus in 2025 was to ensure that veterinary antiemetics in the United States did not pose an unacceptable risk to animal health and to oversee compliance with the regulations related to the manufacturing of such drugs. Zoetis Limitada's Cerenia is the only branded maropitant product for veterinary use in the United States (2007). Maropitant citrate's established product and large companion animal prescription base provides Zoetis with a long-term competitive advantage. Due to the large companion animal population and the significant number of veterinary clinics in the U.S., it is the largest and most developed market for veterinary maropitant products. • China: As of 2025, the CAARA continued to improve the regulatory framework for the veterinary drugs in China and enhanced the inspection of veterinary drug GMP. Increased maropitant manufacturing capacity and the presence of over 120 million pet dogs and cats created a significant market potential for maropitant citrate in China. The standardization and better alignment of pet product regulations should benefit maropitant product approvals in China. • Germany: As of 2025, German national authorities fully applied the EU’s Veterinary Medicine legislation. Local GMP investments and supply partnerships by veterinary medicine manufacturers of the EU allowed for the availability of over 15,000 veterinary medicine products, according to the European Medicines Agency. Germany’s well-established, nationally-regulated network of veterinary clinics will facilitate the supply and pharmacovigilance of maropitant. • India: The Indian Department of Animal Husbandry and Dairying continued developing the oversight of veterinary medicines in 2025. Simultaneously, the private sector initiated the manufacturing of veterinary medicines for companion animals. Preliminary data from the Department’s 2019 livestock census estimated the country’s buffalo and cow population at 303.76 million. Maropitant’s regulatory approval and a reliable manufacturing base will likely be established through the aforementioned reforms. • Japan: Refined regulatory and quality frameworks by the Japanese Ministry of Agriculture, Forestry and Fisheries allowed for the continued import of a diverse range of canine and feline veterinary medicines. The Japan Pet Food Association estimated that, as of 2024, approximately 6.84 million dogs were owned in Japan. Given the current regulatory frameworks, maropitant is only available through veterinary clinics. Features of the Global Maropitant Citrate Market Market Size Estimates: maropitant citrate market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: maropitant citrate market size by various segments, such as by form, species, distribution channel, end use, and region in terms of value ($B). Regional Analysis: maropitant citrate market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different forms, species, distribution channels, end uses, and regions for the maropitant citrate market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the maropitant citrate market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the maropitant citrate market by form (flavored tablet and injectable solution), species (cat and dog), distribution channel (offline pharmacy and online pharmacy), end use (animal specialty hospital, veterinary clinic, and veterinary hospital), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?